BCRX
-
AstraZeneca, Takeda gout acquisitions make BCRX hopeful for gout drug deal
The gout drug candidate BioCryst (NASDAQ:BCRX) is developing now has the green light to advance […]
-
BCRX challenges Biota patent, claims its hepatitis C compound was first
The experimental hepatitis C treatment that BioCryst Pharmaceuticals (NASDAQ:BCRX) wants to take into clinical trials […]
-
Trayt Health Seeks to Increase Access to Diagnoses and Treatments
CEO Malekeh Amini explains how Trayt Health can bridge the gap for patients seeking neurological care.
-
Gout treatment from BCRX shines in trials; company eyes phase 3 or partner
A new gout treatment being developed by BioCryst (NASDAQ:BCRX) has achieved positive phase 2 clinical […]
-
Former Roche executive Abercrombie named to BioCryst board
Former Roche executive George Abercrombie has been elected to BioCryst Pharmaceuticals‘ (NASDAQ:BCRX) board of directors, […]
-
BCRX gout drug looks good in phase 2, but Ardea’s drug looks better
The investigational gout treatment being developed by BioCryst Pharmaceuticals (NASDAQ:BCRX) aims to take an old […]
-
The Dendreon-Provenge Effect: Innocent biotech stocks tumble
North Carolina biotechnology company BioCryst (NASDAQ:BCRX) remains on schedule developing its various drug programs and […]
-
Flu treatment pharma BioCryst turns to stocks for up to $70 million
The NC biotech BioCryst (NASDAQ:BCRX) is turning to Wall Street as another way to stockpile […]
-
NC biotech BioCryst adds healthcare venture capital partner to board
An NC biotech company developing a new flu treatment has named healthcare venture capital veteran […]
-
GSK buys rest of China flu vaccine firm
GlaxoSmithKline (NYSE:GSK) is coughing up $39 million to buy the remaining stake in a joint […]
-
Improving Communication Between Patients and Providers
Sarah Shillington, Chief Customer Officer notes how Artera’s omnichannel platform works.
-
Drug partnering as strategy: How BioCryst plans to move its pipeline
BioCryst Pharmaceuticals CEO Jon Stonehouse got a jump on Memorial Day weekend travel. Today, Stonehouse […]
-
Former Inspire executive Staab named new BioCryst CFO
BioCryst Pharmaceuticals (NASDAQ:BCRX) has hired former Inspire Pharmaceuticals executive Tom Staab to become the drug […]
-
BioCryst invests $5M into pipeline that includes gout, hepatitis C drugs
BioCryst Pharmaceuticals (NASDAQ:BCRX) got its hands on some big dollars in the first three months […]
-
Drug developer BioCryst raises $30M
BioCryst Pharmaceuticals has secured $30 million in new financing through a deal with its Japanese drug partner. BioCryst will use the money for continued R&D.
-
Flu treatment company BioCryst to use $55M for phase III trials
The NC biotech won proposed changes to federal funding that triggered this new infusion of cash. BioCryst Pharmaceuticals’ additional $55 million for flu treatment clinical trials and a new drug application is “money that will get us to the finish line,” CEO Jon Stonehouse said.
-
BioCryst Pharmaceuticals CFO to step down
BioCryst Pharmaceuticals Chief Financial Officer Stuart Grant is resigning from the Durham, North Carolina, company to spend more time with his family following the loss of his son last year.